Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations

Abstract The therapeutic landscape in metastatic melanoma has changed dramatically in the last decade, with the success of immune checkpoint inhibitors resulting in durable responses for a large number of patients. For patients with BRAF mutations, combinations of BRAF and MEK inhibitors demonstrate...

Descripció completa

Dades bibliogràfiques

Autors principals:	Paolo A. Ascierto, Mariaelena Capone, Antonio M. Grimaldi, Domenico Mallardo, Ester Simeone, Gabriele Madonna, Heinrich Roder, Krista Meyer, Senait Asmellash, Carlos Oliveira, Joanna Roder, Julia Grigorieva
Format:	Artigo
Idioma:	Inglês
Publicat:	BMJ Publishing Group 2019-03-01
Col·lecció:	Journal for ImmunoTherapy of Cancer
Matèries:	Immunotherapy Proteomic test Melanoma BRAF mutations Anti-PD-1 Nivolumab
Accés en línia:	http://link.springer.com/article/10.1186/s40425-019-0569-1
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!